Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy

Treatment with aficamten was associated with substantial improvements across a broad range of clinically relevant efficacy measures. These results underscore the wide-ranging potential of aficamten for treatment of patients with symptomatic oHCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with oHCM [SEQUOIA-HCM]; NCT05186818).

Authors

Institutions

Publication Details

Journal
Journal of the American College of Cardiology
Published
2024-09-30
DOI
https://doi.org/10.1016/j.jacc.2024.09.003
Citations
34
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
13.67

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy

Theodore P. Abraham, Roberto Barriales‐Villa, Artur Oręziak, Stephen B. Heitner et al.
34 citations
Journal of the American College of Cardiology
Cardiomyopathy and Myosin Studies
13.67
article

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy

Theodore P. Abraham, Roberto Barriales‐Villa, Artur Oręziak, Stephen B. Heitner, John A. Spertus, Michelle Michels, Michael Arad, Gregory D. Lewis, Iacopo Olivotto, Amy Wohltman, Hugh Watkins, Nuno Cardim, ANJALI TIKU OWENS, Caroline Coats, Brian Claggett, Scott David Solomon, Albert Hagège, Martin S. Maron, Matthew M.Y. Lee, Pablo García‐Pavía, Daniel Jacoby, Ahmad Masri, Fady I. Malik, Ian J. Kulac, Stuart Kupfer, Lisa Meng, Lubna Choudhury, Michael E. Nassif, Marion van Sinttruije, Changsheng Ma, Josef Veselka, Jacob Tfelt‐Hansen, Hans‐Dirk Düngen, James L. Januzzi
article en
34 citations

Abstract

Treatment with aficamten was associated with substantial improvements across a broad range of clinically relevant efficacy measures. These results underscore the wide-ranging potential of aficamten for treatment of patients with symptomatic oHCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with oHCM [SEQUOIA-HCM]; NCT05186818).

Journal of the American College of CardiologyVol. 84(19)
Northwestern University (US), University of Copenhagen (DK), Brigham and Women's Hospital (US), Lahey Hospital and Medical Center (US), Saint Luke's Health System (US), Harvard University (US), Oregon Health & Science University (US), University of California, San Francisco (US), Capital Medical University (CN), Sheba Medical Center (IL), Erasmus MC (NL), Copenhagen University Hospital (DK), University of Oxford (GB), Massachusetts General Hospital (US), Centro de Investigación en Red en Enfermedades Cardiovasculares (ES), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Européen Georges-Pompidou (FR), Lahey Medical Center (US), Baim Institute for Clinical Research (US), Viaa Christian University of Applied Sciences (NL), Meyer Children's Hospital (IT), Centro de Investigación Biomédica en Red (ES), Beijing Anzhen Hospital (CN), Institute of Cardiology (PL), Saint Luke's Hospital (US), Cytokinetics (United States) (US), Complexo Hospitalario Universitario A Coruña (ES), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Instituto de Investigación Biomédica de A Coruña (ES), Klinikum Chemnitz (DE), Hospital do Desterro (PT), Hospital CUF Descobertas, Technische Universität Dresden (DE), Charité - Universitätsmedizin Berlin (DE), University of Glasgow (GB), University of Pennsylvania (US), Erasmus University Rotterdam (NL)
Cytokinetics
Openalex Percentile: Top 1%
Cardiomyopathy and Myosin Studies
13.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.